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T
he many splendors of ¢brin go far beyond its intrin-
sic role in hemostasis. Fibrin indirectly contributes to
the healing of injured tissue through its ability to
bind proenzymes, enzyme inhibitors, extracellular
matrix molecules and cells (Clark, 2001). In this issue
of the Journal Greer and Andreadis (2003) extend the multiplicity
of ¢brin functions during wound repair. They demonstrate that
by its capacity to bind plasminogen, ¢brin indirectly promotes
epidermal cell migration. This concept is especially attractive
since epidermal cells do not express a receptor for ¢brin (Kubo
et al, 2001), yet ¢brin has been reported to facilitate epithelializa-
tion in vitro (Greer et al, 2002) and in vivo (Horch et al, 1998; Pelle-
grini et al, 1999). To better appreciate the multitude of molecules
that can interact with the ¢brin clot, a brief overview of the
structure and function of ¢brinogen and ¢brin is warranted.
Fibrinogen is a 340-kDa hexameric glycoprotein composed of
pairs of three gene products, namely: 2 Aa chains, 2 Bb chains,
and 2 g-chains (Fig 1) (Mosesson et al, 2001). It is synthesized by
the liver and circulates in the blood at approximately 3 mg/ml.
The three ¢brinogen chains are encoded by distinct genes located
in close proximity on the long arm of chromosome 4. Disul¢de
bonds occur between the amino terminal ends of the three chains,
resulting in a half-molecule of ¢brinogen. Dimerization of two
half molecules in an antiparallel con¢guration results from
further disul¢de bond formation between additional cysteine
residues in the amino-terminal region of the Aa, Bb and g chains
(Fig 1). Electron microscopy studies of ¢brinogen demonstrate a
trinodular structure. The central nodule represents the amino-
terminal disul¢de knot of the six chains (so-called E domain)
(Fig 1). The two end nodules represent the carboxyl terminal
regions of the Bb and g chains (so-called D domains) and are
connected to the central nodule by a rod-like a-helical, coiled
coil region. The carboxyl terminus of the Aa chain is more £ex-
ible than the rest of the ¢brinogen molecule and folds back onto
the E domain. Many of the binding sites for cells and other mo-
lecules on ¢brinogen and ¢brin are indicated in Fig 1.
The last step in the blood coagulation pathway involves the
conversion of ¢brinogen to ¢brin by the enzyme thrombin.
Thrombin cleavage of ¢brinopeptide A (FPA) and ¢brinopeptide
B (FPB) from the amino-terminus of ¢brinogen exposes pre-
viously cryptic sites, which function cooperatively in ¢brin poly-
merization (Fig 1). After the release of FPA, new a chain amino
terminal ends are generated which interact with sites in the g
chain carboxyl termini of adjacent molecules to promote non-
covalent lateral assembly. Subsequent removal of the FPB creates
new b chain amino terminal ends that also interact with sites in
the g chain carboxyl termini of adjacent molecules, reinforcing
lateral aggregation and leading to thicker ¢ber formation. Fibrin
thus polymerizes in a staggered overlapping manner into proto-
¢brils. Subsequently, lateral proto¢bril associations occur, result-
ing in thick ¢brin ¢bers that intertwine to produce a clot.
For e¡ective hemostasis, the ¢brin clot must interact with plate-
lets. This interaction is mediated by the platelet membrane
receptor GPIIb-IIIa (aIIbb3 integrin) (Du et al, 1997). The resul-
tant clot, however, is friable. Stability is conferred by covalent
crosslinking of adjacent ¢brin ¢brils. The crosslinks are formed
by plasma transglutaminase (factor XIIIa) which catalyzes e-(g-
glutamyl)lysine [e-(g-glu)lys] isopeptide bonds. The biochemical
structure of a ¢brin clot is dynamic and becomes a more stable
hemostatic plug with time.
The ¢brin clot, however, is much more than a hemostatic plug.
As it becomes ¢rmly integrated in wounded tissue it provides a
sca¡old for cell migration and proliferation; a reservoir for
growth factors, proteases and protease inhibitors; and a modula-
tor of cell function. How does it do this?
Fibrin has the capacity to bind other blood-borne, provisional
matrix proteins including ¢bronectin (Makogonenko et al, 2002),
Figure1. Schematic diagram of ¢brinogen and ¢brin showing the major
structural domains, the association sites that participate in ¢brin polymer-
ization and crosslinking, and some molecular and cellular binding interac-
tions. (reprinted after modi¢cations with permission from Mosesson et al,
Ann NYAcad Sci 936:11^30, 2001). Fibrinopeptide A (FPA), ¢brinopeptide
B (FPB), plasmin inhibitor (PI), plasminogen activator inhibitor (PAI), tis-
sue plasminogen activator (tPA). (Modi¢ed from Ann NYAcad Sci 936:11^
30, 2001, with permission).
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vitronectin (Preissner and Jenne, 1991), and thrombospondin
(Bacon-Baguley et al, 1990). The ability of ¢brin to convey these
matrix proteins to the early wound clearly ampli¢es the ability of
the ¢brin clot to support tissue cell migration (Greiling and
Clark, 1997).
Fibrin also binds a number of growth factors both directly and
indirectly. Direct binding occurs with thrombin (Pospisil et al,
2003), basic ¢broblast growth factor (bFGF) (Sahni et al, 1998),
platelet-derived growth factor (PDGF) and transforming growth
factor-beta (TGF-b) (Cullen and Clark, unpublished observa-
tions). Since ¢brin has the capacity to bind heparin (Odrljin
et al, 1996), it may indirectly bind heparin-binding growth
factors, such as bFGF, heparin-binding epidermal growth factor
(HB-EGF), PDGF and VEGF. Fibrin may bind TGF-b either
directly or indirectly since ¢brin binds ¢bronectin and ¢bronec-
tin binds TFG-b (Fava and McClure, 1987). Even more complex,
insulin-like growth factor binding protein-3 (IGFBP-3) binds
¢bronectin (Gui and Murphy, 2001) and then this complex could
potentially bind insulin-like growth factor (IGF). Regardless of
the exact mechanism, ¢brin can carry and retain growth factors
in the wound clot, and the presence of such growth factors in the
wound clot may be critical for healing to commence vis-aØ -vis the
stimulation of tissue cell migration and proliferation (Yamada and
Clark, 1996).
Finally, enzymes, such as thrombin (Pospisil et al, 2003) and tis-
sue plasminogen activator (tPA)(Tsurupa and Medved, 2001);
proenzymes, such as plasminogen (Tsurupa and Medved, 2001);
and enzyme inhibitors, such as plasminogen activator inhibitor
(PAI) (Wagner et al, 1989) and a2-plasmin inhibitor (Sakata and
Aoki, 1980) can bind to ¢brin and thereby control the balance be-
tween further coagulation and ¢brinolysis. In addition tPA and
plasmin, once activated, can activate matrix metalloproteinases
(MMPs) (Mignatti et al, 1996). Collectively these enzymes can pro-
mote extracellular matrix (ECM) degradation and concomitant
cell migration through the ‘‘loosening’’ of the pericellular matrix.
Platelets and some tissue cells can directly bind ¢brin through
integrin receptors (Cheresh et al, 1989). Integrins are transmem-
brane heterodimeric glycoproteins that can bind ECM and
trigger signal transduction cascades (Miyamoto et al, 1998). On
the cell surface integrins can complex with growth factors and
MMPs. In the cell, integrin triggered signal pathways integrate
with those emanating from growth factor ligation. As mentioned
above, platelets bind ¢brin through the platelet membrane recep-
tor GPIIb-IIIa (aIIbb3 integrin) (Du and Ginsberg, 1997). In con-
trast, the major ¢brin receptor on other cells is the integrin avb3
(Cheresh et al, 1989). Endothelial cells can express great quantities
of avb3, especially on the tips of angiogenic sprouts (Clark et al,
1996). However, ¢broblasts have lesser amounts of this receptor
(Gailit et al, 1997) and epidermal cells express none, even under
wounded conditions (Kubo et al, 2001). Thus, reports that ¢brin
a¡ects the activity of epidermal cells may at ¢rst appear puzzling.
The paper by Greer and Andreadis in this month’s Journal helps
explain the apparent contradiction.
Wisely, Greer and Andreadis looked beyond ¢brin itself for the
mechanism by which ¢brin enhanced the migration of human
keratinocytes and found that plasminogen (plasmin) was the
source of the enhanced activity. That plasmin can promote cell
migration is not novel, as such activity has been described for
cells in general (Murphy and Gavrilovic, 1999) and keratinocytes
in particular (Ronfard and Barrandon, 2001). The important con-
cept is that ¢brin may carry su⁄cient plasminogen and tPA to
initiate the process.
The other side of the coin occurs if investigators do not
attempt to decipher the mechanism of ¢brin activity in a system.
Most commercial preparations of ¢brinogen are crude at best and
are therefore ‘‘contaminated’’ with other matrix proteins, like ¢-
bronectin (Greiling and Clark, 1997), growth factors, enzymes,
enzyme inhibitors, and proenzymes like plasminogen, as re-
ported by Greer and Andreadis. It can be quite di⁄cult to deter-
mine the source of activity in a ¢brin preparation and even more
troublesome to obtain adequately puri¢ed ¢brinogen. Fibrin is
truly ‘‘a many splendored thing’’, both for its intrinsic activities
and for its a⁄nity for other biologically active molecules.
The author wishes to thank Marcia G.Tonnesen, M.D. for making many helpful
suggestions regarding the manuscript.
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